Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Lisocabtagene maraleucel |
Trade Name | Breyanzi |
Synonyms | JCAR 017|JCAR017|JCAR-017 |
Drug Descriptions |
Breyanzi (lisocabtagene maraleucel) comprises equal amount of CD4+ and CD8+ autologous T lymphocytes engineered to express chimeric antigen receptors containing an anti-CD19 fragment fused to the 4-1BB (CD137) signaling domain, which may result in immune-modulating and anti-tumor activities (PMID: 32888407). Breyanzi (lisocabtagene maraleucel) is FDA approved for use in patients with large B-cell lymphoma including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who are refractory to or relapsed within 12 months of first-line immunochemotherapy, or have refractory or relapsed disease after first-line immunochemotherapy and not eligible for hematopoietic stem cell transplantation, or have relapsed or refractory disease after two or more lines of systemic therapy, and in patients with relapsed or refractory mantle cell lymphoma who have received at least two prior lines of systemic therapy (FDA.gov). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | C125192 |